Asthma Clinical Trial
Official title:
Exhaled Hydrogen Sulphide as a Biomarker of Airways Disease in Asthma
The purpose of this study will be to determine whether there is any role for measuring
Hydrogen Sulphide (H2S) in the exhaled breath in terms of management of the patient with
asthma.
The investigators will recruit patients with a range of severity of asthma and health
volunteers. Levels of Hydrogen Sulphide will be measured in exhaled breath and blood. Also
exhaled Nitric Oxide, Spirometry and asthma symptom scores will be measured at each study
visit. Participants will attend either 2 or 4 separate visits.
The investigators will determine whether there is a relationship between exhaled Hydrogen
Sulphide and asthma severity.
Objectives:
1. Perform a cross-sectional study in non-asthmatic subjects and asthmatic subjects of
varying severities of the levels of Hydrogen Sulphide in exhaled breath in relation to
the severity and control of asthma
2. Compare the levels of exhaled Hydrogen Sulphide with exhaled Nitric Oxide.
We will recruit 30 health volunteers and 90 patients with a range of severity of asthma.
Particpants will attend for either 2 or 4 visits. At these visits the following measurements
will be taken:
1. Exhaled Hydrogen Sulphide
2. Serum Hydrogen Sulphide
2. Exhaled Nitric Oxide 3. Spirometry 4. Asthma Symptom Score (ACQ)
The investigators will use a Hydrogen Sulphide UV fluorescent machine Model T101 (0-50 ppb to
0-20 ppm) (Cal-Bay Control Inc, USA) to measure directly on line exhaled breath Hydrogen
Sulphide. This method has been used previously in normal people, but we will first determine
whether there is an exhaled flow-dependence on the measurement of H2S levels. The
investigators will use a hand-held Nitric Oxide machine (NO Breath) to measure Nitric Oxide
in exhaled breath.
Subjects must have asthma according to one or more of the following criteria documented in
the last 12 months:
1. Improvement in FEV1 (forced expiratory volume at one second) ≥ 12% and 200ml predicted
after inhalation of 400 mcg salbutamol
2. Airway hyper-responsiveness (PC20 <8mg/ml)
3. Diurnal variation in PEF (peak expiratory flow): amplitude % mean of twice daily PEF >
8%
4. Decrease in pre-bronchodilator FEV1 >12% and >200mls within 4 weeks after tapering
treatment with one or more of the following drugs: inhaled corticosteroids, oral
corticosteroids, long-acting beta-agonists, long-acting beta-agonists and short-acting
beta-agonists.
PLUS A history of wheeze occurring spontaneously or on exertion
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
| Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
| Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
| Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
| Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
| Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
| Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
| Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
| Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
| Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
| Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
| Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
| Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
| Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
| Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
| Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
| Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
| Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
| Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
| Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|